$SRTA

Cohen Amir sold $60K of SRTA

Cohen Amir (Chief Accounting Officer) sold 10,300 shares of Strata Critical Medical, Inc. (SRTA) at $5.79 on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cohen Amir
Published May 26, 2026, 8:49 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SRTA
Neutral
medium confidence
Mentioned
$SRTA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRTANeutralLow
01

Why it matters

The officer sold $59,637 worth of shares via an open-market transaction under a pre-arranged 10b5-1 plan; absent other news, this is more sentiment/positioning than fundamental repricing.

02

Market read

A disclosed 10b5-1 insider sale can cause short-term noise, but it is usually not a strong standalone trading catalyst.

03

What to watch

Traders may overreact to the headline; the key is whether there are repeated insider sales or concurrent negative fundamentals not present in this article.

Relevance 6/10Timing: Filed 2026-05-26 for a sale executed 2026-05-21; impact, if any, is most relevant around filing/next session.

Background

The article is an SEC Form 4 insider transaction disclosure for Strata Critical Medical, Inc. (SRTA).

Company-level read

Ticker impact

$SRTANeutralMedium confidence
Context

Cohen Amir (Chief Accounting Officer) filed an open-market sale of 10,300 SRTA shares at $5.7900 on a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any reaction should fade unless accompanied by other company-specific catalysts.

Evidence & confidence

The disclosure is an officer transaction under a pre-arranged 10b5-1 plan, with no accompanying operational or financial news in the filing.

Market effects

Minimal—this is a single-company insider transaction with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity needs rather than negative expectations.

Key entities

  • Strata Critical Medical, Inc.

    Subject of the SEC Form 4 insider transaction; Chief Accounting Officer sold 10,300 shares at $5.7900.

  • Cohen Amir

    Chief Accounting Officer who executed the sale under a 10b5-1 plan.

Related articles

$SRTAMed

Strata Critical Medical, Inc. (SRTA): Results of Operations and Financial Condition

Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 srta-earningreleasexq22026.htm EX-99.1 Document Exhibit 99.1 August 4, 2026 Strata Critical Medical Announces Second Quarter 2026 Results • Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 • Clinical revenue increased 22.6% sequentially in Q2 2026; Exc